A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Summary

This study will evaluate the safety and tolerability of ABBV-0805 in adult participants with Parkinson's Disease and results from it will help guide the design of future clinical studies. ABBV-0805 is administered every 28 days by intravenous (IV) infusion.

Timeline

Start

2020-03-03

Primary completion

2020-06-16

Completion

2020-06-16

Outcome

Outcome not reported

Stopped (Business): “Strategic considerations”

Drugs

Indications